<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(3)</volume><submitter>Gonzalez M</submitter><pubmed_abstract>This two-sequence, three-period study (NCT04645940) was designed to evaluate the effect of food and concomitant rabeprazole, a proton pump inhibitor, on the pharmacokinetics (PK) and safety of fruquintinib and its metabolite M11 after a single oral dose of fruquintinib 5 mg in healthy subjects. In the food effect treatment periods, 14 subjects were randomized in a 1:1 ratio utilizing a two-sequence (fed/fasted vs. fasted/fed), two-period, cross-over design. Fruquintinib was administered on Day 1 (Period 1) and Day 15 (Period 2). In the drug-interaction period (Period 3), all subjects received rabeprazole 40 mg 1 h prior to fruquintinib under fasted conditions, following a 6-day lead-in of rabeprazole 40 mg once daily. PK samples to measure fruquintinib and M11 were collected pre-dose and o</pubmed_abstract><journal>Clinical and translational science</journal><pagination>e70168</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11903327</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Assessment of Food Effect and pH-Dependent Drug-Drug Interactions of Fruquintinib in Healthy Subjects.</pubmed_title><pmcid>PMC11903327</pmcid><pubmed_authors>Chien C</pubmed_authors><pubmed_authors>Yang Z</pubmed_authors><pubmed_authors>Gonzalez M</pubmed_authors><pubmed_authors>Schelman WR</pubmed_authors><pubmed_authors>Gupta N</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Assessment of Food Effect and pH-Dependent Drug-Drug Interactions of Fruquintinib in Healthy Subjects.</name><description>This two-sequence, three-period study (NCT04645940) was designed to evaluate the effect of food and concomitant rabeprazole, a proton pump inhibitor, on the pharmacokinetics (PK) and safety of fruquintinib and its metabolite M11 after a single oral dose of fruquintinib 5 mg in healthy subjects. In the food effect treatment periods, 14 subjects were randomized in a 1:1 ratio utilizing a two-sequence (fed/fasted vs. fasted/fed), two-period, cross-over design. Fruquintinib was administered on Day 1 (Period 1) and Day 15 (Period 2). In the drug-interaction period (Period 3), all subjects received rabeprazole 40 mg 1 h prior to fruquintinib under fasted conditions, following a 6-day lead-in of rabeprazole 40 mg once daily. PK samples to measure fruquintinib and M11 were collected pre-dose and o</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-07-15T14:39:47.253Z</modification><creation>2025-04-04T09:06:52.801Z</creation></dates><accession>S-EPMC11903327</accession><cross_references><pubmed>40077903</pubmed><doi>10.1111/cts.70168</doi></cross_references></HashMap>